# Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials

> **NCT05492578** · PHASE2,PHASE3 · ENROLLING_BY_INVITATION · sponsor: **Sanofi** · enrollment: 1663 (estimated)

## Conditions studied

- Dermatitis Atopic

## Interventions

- **DRUG:** Amlitelimab
- **DRUG:** Topical corticosteroids
- **DRUG:** Topical calcineurin inhibitors
- **DRUG:** Oral corticosteroids

## Key facts

- **NCT ID:** NCT05492578
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2022-08-22
- **Primary completion:** 2029-01-22
- **Final completion:** 2029-01-22
- **Target enrollment:** 1663 (ESTIMATED)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05492578

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05492578, "Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05492578. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*